Semax dosing: what the trials used

Search for "Semax dose" and you will find a range of numbers cited with varying confidence across nootropic forums, vendor pages and grey-market clinic guides. Most trace back to a handful of Russian clinical studies and a parallel body of rodent mechanistic work. This article documents what those studies actually administered, why the dose picture is fragmented, and what the evidentiary gaps mean. For the full compound profile, see the Semax peptide page.

The Russian stroke trials: what clinicians administered

The most-cited human data comes from Russian academic groups working in the ischemic stroke indication. Gusev and colleagues published the earliest controlled study in 1997 (PMID 11517472), enrolling 30 patients with acute hemispheric ischemic stroke alongside an 80-patient standard-therapy control group^[1]. The trial administered Semax intranasally at 12 mg per day for moderate-severity cases and 18 mg per day for severe cases, with treatment durations of 5 and 10 days respectively. The authors reported accelerated regression of motor and focal neurological disorders and improvements on clinical and electrophysiological measures.

A second study from the same group (Miasoedova et al., 1999; PMID 10358912) investigated the neuroprotective mechanism in acute ischemic stroke^[2]. In experimental components of that work the investigators used 100 to 150 micrograms per kilogram. The 1999 paper described Semax's effects as angioprotective, antihypoxic and neurotrophic, and characterised changes in inflammatory markers (interleukin-10, TNF-alpha, interleukin-8, C-reactive protein) in treated patients.

The largest clinical study published to date is Gusev et al. (2018; PMID 29798983), which enrolled 110 patients at different stages of post-stroke rehabilitation^[3]. The trial administered Semax as two 10-day intranasal courses at 6,000 micrograms per day (6 mg/day), separated by a 20-day interval. That 6 mg/day figure is the dose most commonly referenced when the 2018 study is cited. The investigators measured plasma brain-derived neurotrophic factor (BDNF) alongside motor and functional recovery outcomes (BMRC motor scale and Barthel index), reporting improvements regardless of rehabilitation timing, with greater effect in the early rehabilitation group.

Preclinical mechanistic studies: what researchers used in rodents

The mechanistic picture comes mostly from rat studies. Dolotov and colleagues (2006; PMID 16635254) examined the BDNF-elevating effect of intranasal Semax in male Wistar rats^[4]. They administered Semax intranasally at 50 micrograms per kilogram and at 250 micrograms per kilogram, and measured BDNF protein in brain tissue three hours post-application. Both doses raised BDNF in the basal forebrain; the cerebellum did not respond, indicating regional specificity. That regional pattern is one reason the compound is framed as a neuroprotective and nootropic agent rather than a systemic hormone.

Eremin and colleagues (2005; PMID 16362768) focused on neurochemical signalling, injecting Semax intraperitoneally at 0.15 mg per kilogram in rodents, then measuring striatal serotonin metabolites and dopamine responses when combined with amphetamine^[5]. Striatal 5-HIAA rose approximately 25% two hours after Semax administration alone; the combined Semax-amphetamine paradigm produced a substantial amplification of dopamine release. The authors framed this as evidence of positive modulatory effects on both the serotoninergic and dopaminergic systems, which aligns with the nootropic framing in Russian clinical practice.

More recent rodent work has extended the dose picture into new models. A 2025 British Journal of Pharmacology paper (Liu et al.; PMID 40692165) used Semax in female C57BL/6 mice with spinal cord injury at T9-T10, measuring functional recovery with Basso scores, footprint analysis and inclined plane tests^[6]. The study identified a mu-opioid receptor mechanism (through the Oprm1 gene) and effects on lysosomal membrane stability and pyroptosis. Specific dosing details were not reported in the abstract, and the mechanism observed here is distinct from the BDNF pathway characterised in the basal forebrain work.

Why the numbers differ across papers

Three factors explain why the dose figures in the Semax literature span a wide range and are hard to compare directly. First, route of administration differs: the Russian clinical stroke trials used intranasal delivery, while some preclinical mechanistic studies used intraperitoneal injection. Bioavailability differs by route in ways that have not been formally characterised for Semax in published human pharmacokinetic work. Second, the indication differs: the Russian stroke trials were dosing for an acute neurological emergency with a defined treatment window; the rodent mechanistic studies were using doses selected to produce a measurable biochemical signal, not to treat a disease. Third, the human trial doses (6 mg/day, 12 mg/day, 18 mg/day) are reported in milligrams of total intranasal daily dose, while the rodent studies report in micrograms per kilogram body weight, and no conversion factor between the two has been validated in a controlled pharmacokinetic study.

What we still do not know

The evidentiary gaps are significant. There is no published dose-response study in healthy humans for any cognitive or nootropic endpoint. The Russian clinical trials established doses used in the stroke indication but did not characterise a dose-response curve: none reported a systematic comparison of, say, 3 mg/day versus 6 mg/day versus 12 mg/day in the same patient population. There is no published pharmacokinetic study in humans that characterises intranasal bioavailability, peak plasma concentration, or half-life. There is no long-term human safety dataset from a controlled trial. And because Semax has no marketing authorisation in the EU, EEA, UK or US, there is no regulator-approved prescribing information that specifies a validated human dose for any Western jurisdiction. For per-country regulatory status, see the Semax regulation section.

The bottom line for readers

Every published human dose figure for Semax comes from the Russian stroke trials. The most widely referenced is 6,000 micrograms per day (given intranasally in two 10-day courses) from Gusev et al. (2018). The 12 mg and 18 mg per day doses from the 1997 Gusev study apply to different stroke severity categories. None of these figures has been validated in a Western-standard randomised controlled trial, and none constitutes a recommended dose for non-stroke uses, for healthy individuals, or for the nootropic applications discussed online. If you are considering Semax, that conversation belongs with a clinician who knows your medical history and has read the original Russian literature, not with a vendor dosing guide.